SCINTIX™ technology is a novel therapy for patients with any stage of cancer - even those with metastatic disease. This breakthrough technology utilizes live, continuously updated motion management data throughout the entire treatment session.
Download Whitepaper
The RefleXionⓇ X1 is the only platform that can leverage the rapidly expanding universe of novel radiotracers – molecules that are clinically proven to more accurately target cancer over other imaging modalities.
SCINTIX therapy has the potential to treat tumors of any stage with conformal dose delivery and smaller margins, resulting in less toxicity to improve patient outcomes.
Our SCINTIX technology tracks expected tumor motion caused by physiologic processes, and motion you don’t expect, like that from surprise shifts in patient positioning.
The RefleXionⓇ X1 is the only platform that can leverage the rapidly expanding universe of novel radiotracers – molecules that are clinically proven to more accurately target cancer over other imaging modalities.
SCINTIX therapy has the potential to treat tumors of any stage with conformal dose delivery and smaller margins, resulting in less toxicity to improve patient outcomes.
Our SCINTIX technology tracks expected tumor motion caused by physiologic processes, and motion you don’t expect, like that from surprise shifts in patient positioning.
The RefleXion X1 with SCINTIX technology marries PET and CT, proven modalities for visualizing cancer, with radiotherapy, one of the most effective ways of treating cancer in a dual modality platform.
By combining radiotherapy and PET-CT in a novel way,
we can find and treat cancer using its own emissions.
State-of-the-art SBRT and IMRT.
Learn more about RefleXion 16 slice, fan-beam kVCT imaging.
See inside the RefleXion X1 machine.
Learn more about RefleXion
SCINTIX therapy uses PET – the gold standard in cancer imaging – in a new way to solve the conundrum of tumor motion. A single radiotracer injection turns each cancer into a biological beacon that communicates data about the cancer’s location, via a continuous stream of PET emissions. As the tracer accumulates in tumors, onboard PET detectors on the X1 machine sense the emissions and use these data to guide treatment delivery with sub-second latency.
Watch Video
For cancer patients with tumors of any stage, SCINTIX biology-guided radiotherapy (BgRT) creates a new definitive treatment option. SCINTIX therapy brings the cost effectiveness and efficacy of radiotherapy to more advanced staged cancers. Because SCINTIX technology uses tumor emissions created during delivery to guide therapy, clinicians no longer construct plans for moving tumors using an ITV approach that radiates a large volume. Instead, the PTV may be more conformal to spare healthy tissue and preserve dose for additional tumors.
WATCH VIDEO
SCINTIX therapy elevates the performance of radiotracers from a diagnostic tool to precise therapeutic guidance. Initially compatible with FDG, RefleXion seeks to enable biology-guided radiotherapy for other disease-specific tracers. We have forged collaboration agreements with industry-leading radiopharmaceutical manufacturers to develop both fluorine and gallium PSMA tracers that will one day expand SCINTIX therapy to include all stages of prostate cancer.
WATCH VIDEO
The RefleXion X1 with SCINTIX therapy is the only dual modality platform offering biologic guidance for tumors in motion, and anatomic guidance for earlier stage cancers via its onboard fan-beam kVCT. Beyond BgRT, the X1 is cleared for conventional SBRT, IMRT and SRS to create a workhorse platform that fits in most standard vaults without the need for additional shielding or expensive construction.
WATCH VIDEO
A closer look at the proprietary technologies that combine to create our game-changing approach to cancer treatment.
See how SCINTIX therapy combines PET and CT with radiotherapy in a novel way.
View the latest evidence-based research and peer-reviewed articles.
Our PREMIER registry is a prospective, real-world, clinical outcomes registry for patients with all stages of cancer.
See how SCINTIX therapy combines PET and CT with radiotherapy in a novel way.
View the latest evidence-based research and peer-reviewed articles.
Our PREMIER registry is a prospective, real-world, clinical outcomes registry for patients with all stages of cancer.
Let us tell you more.
Contact UsStay up to date.
Sign Up